PTK7 and breast carcinoma: In a breast cancer‐bearing mouse model, a single low dose of MedTACPTK7 (0.5 mg kg−1) reduced protein tyrosine kinase‐7 (PTK7) levels by up to 80% within 24 h, with sustained degradation of 44% at 72 h, demonstrating excellent pharmacokinetics.